



**Wolfgang C Korte**

**Kontakt**

Wolfgang C Korte

## Publikationen (7)

Woelfel S, Junker D, Bergamin I, Meyer-Herbon P, Stillhard R, Graf N, Leinenkugel G, Dütschler J, König M, Häuptle R, Zwyszig S, Krieger-Grübel C, Truniger S, Koller S, Metzger-Peter K, Frei N, Genetics And Observational Subarachnoid Haemorrhage Gosh Study Investigators, Albrich W, Friedrich M, Bernsmeier C, Niess J, Korte W, Bürgi J, Dulovic A, Schneiderhan-Marra N, Semela D, Brand S. STAR LIGHT Study: XBB.1.5 COVID-19 mRNA Vaccines Boost Systemic but Not Mucosal Immunity Against the SARS-CoV-2 JN.1 Variant in Patients with Chronic Liver Disease. *Vaccines (Basel)* 2024; 12

Woelfel S, Dütschler J, Junker D, König M, Graf N, Krieger-Grübel C, Truniger S, Oikonomou V, Leinenkugel G, Koller S, Metzger-Peter K, Wyss J, Krupka N, Frei N, STAR SIGN Study Investigators, Albrich W, Friedrich M, Niess J, Schneiderhan-Marra N, Dulovic A, Misselwitz B, Korte W, Bürgi J, Brand S. XBB.1.5-Adapted COVID-19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS-CoV-2 JN.1 Variant in Patients With Inflammatory Bowel Disease. *Aliment Pharmacol Ther* 2024

Woelfel S, Dütschler J, Junker D, König M, Leinenkugel G, Graf N, Krieger-Grübel C, Truniger S, Franke A, Koller S, Metzger-Peter K, Oberholzer M, Frei N, Geissler N, Schaub P, Genetics And Observational Subarachnoid Haemorrhage Gosh Study Investigators, Albrich W, Friedrich M, Niess J, Schneiderhan-Marra N, Dulovic A, Korte W, Bürgi J, Brand S. Systemic and Mucosal Immunogenicity of Monovalent XBB.1.5-Adapted COVID-19 mRNA Vaccines in Patients with Inflammatory Bowel Disease. *Vaccines (Basel)* 2024; 12

Woelfel S, Dütschler J, König M, Dulovic A, Graf N, Junker D, Oikonomou V, Krieger-Grübel C, Truniger S, Franke A, Eckhold A, Forsch K, Koller S, Wyss J, Krupka N, Oberholzer M, Frei N, Geissler N, Schaub P, STAR SIGN Study Investigators, Albrich W, Friedrich M, Schneiderhan-Marra N, Misselwitz B, Korte W, Bürgi J, Brand S. STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease. *Aliment Pharmacol Ther* 2023; 58:678–691.

Woelfel S, Dütschler J, König M, Graf N, Oikonomou V, Krieger-Grübel C, Truniger S, Franke A, Eckhold A, Forsch K, Wyss J, Krupka N, Albrich W, Frei N, Geissler N, Schaub P, STAR SIGN Study Investigators, Friedrich M, Misselwitz B, Korte W, Bürgi J, Brand S. Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2. *Aliment Pharmacol Ther* 2022; 57:103–116.

Jámbor C, Reul V, Schnider T, Degiacomi P, Metzner H, Korte W. In vitro inhibition of factor XIII retards clot formation, reduces clot firmness, and increases fibrinolytic effects in whole blood. *Anesthesia and analgesia* 2009; 109:1023–8.

Korte W, Lange J, Devay J, Zoller N, Degiacomi P, Eder M, Kownacki E, Gabi K, Gähler A, Szadkowski C, Schnider T. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. *Anesthesiology* 2009; 110:239–45.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)